Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

Articles published in
BMC Cancer
    July 2021
  1. LI J, Cao J, Li P, Yao Z, et al
    Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    BMC Cancer. 2021;21:858.
    >> Share

  2. TANG X, Qian WL, Yan WF, Pang T, et al
    Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study.
    BMC Cancer. 2021;21:823.
    >> Share

  3. FU Y, Sun S, Bi J, Kong C, et al
    A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer.
    BMC Cancer. 2021;21:810.
    >> Share

    June 2021
  4. WANG Z, Tu L, Chen M, Tong S, et al
    Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    BMC Cancer. 2021;21:692.
    >> Share

  5. RIPOLL J, Ramos M, Montano J, Pons J, et al
    Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival.
    BMC Cancer. 2021;21:676.
    >> Share

    May 2021
  6. LYU X, Wang P, Qiao Q, Jiang Y, et al
    Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    BMC Cancer. 2021;21:646.
    >> Share

  7. CHEN X, Lin X, Pang G, Deng J, et al
    Significance of KDM6A mutation in bladder cancer immune escape.
    BMC Cancer. 2021;21:635.
    >> Share

  8. CHAN LC, Kalyanasundram J, Leong SW, Masarudin MJ, et al
    Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes.
    BMC Cancer. 2021;21:625.
    >> Share

    April 2021
  9. ZHANG Z, Yu Y, Zhang P, Ma G, et al
    Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
    BMC Cancer. 2021;21:458.
    >> Share

  10. MANZANO RG, Catalan-Latorre A, Brugarolas A
    RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    BMC Cancer. 2021;21:432.
    >> Share

    March 2021
  11. MIYAKE M, Iida K, Nishimura N, Miyamoto T, et al
    Non-maintenance intravesical Bacillus Calmette-Guerin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
    BMC Cancer. 2021;21:266.
    >> Share

  12. CHEN F, Wang Q, Zhou Y
    The construction and validation of an RNA binding protein-related prognostic model for bladder cancer.
    BMC Cancer. 2021;21:244.
    >> Share

    January 2021
  13. YONEYAMA T, Hatakeyama S, Sutoh Yoneyama M, Yoshiya T, et al
    Tumor vasculature-targeted (10)B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy.
    BMC Cancer. 2021;21:72.
    >> Share

  14. PORRECA A, Palmer K, Artibani W, Antonelli A, et al
    Protocol of the Italian Radical Cystectomy Registry (RIC): a non-randomized, 24-month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer.
    BMC Cancer. 2021;21:51.
    >> Share

  15. OKAMURA S, Yoshino H, Kuroshima K, Tsuruda M, et al
    EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.
    BMC Cancer. 2021;21:48.
    >> Share

    December 2020
  16. KIM TM, Yoo JS, Moon HW, Hur KJ, et al
    Distinct mutation profiles between primary bladder cancer and circulating tumor cells warrant the use of circulating tumors cells as cellular resource for mutation follow-up.
    BMC Cancer. 2020;20:1203.
    >> Share

  17. JOHN A, Gunes C, Bolenz C, Vidal-Y-Sy S, et al
    Bladder cancer-derived interleukin-1 converts the vascular endothelium into a pro-inflammatory and pro-coagulatory surface.
    BMC Cancer. 2020;20:1178.
    >> Share

    November 2020
  18. ZHAI M, Tang C, Li M, Chen X, et al
    Short-term mortality risks among patients with non-metastatic bladder cancer.
    BMC Cancer. 2020;20:1148.
    >> Share

    October 2020
  19. LIU B, Sun W, Gao W, Li L, et al
    microRNA-451a promoter methylation regulated by DNMT3B expedites bladder cancer development via the EPHA2/PI3K/AKT axis.
    BMC Cancer. 2020;20:1019.
    >> Share

    September 2020
  20. KOTECHA P, Moss CL, Enting D, Gillett C, et al
    Cohort profile: King's Health Partners bladder cancer biobank.
    BMC Cancer. 2020;20:920.
    >> Share

  21. MATHEUS LHG, Dalmazzo SV, Brito RBO, Pereira LA, et al
    1-Methyl-D-tryptophan activates aryl hydrocarbon receptor, a pathway associated with bladder cancer progression.
    BMC Cancer. 2020;20:869.
    >> Share

  22. TIAN Z, Meng L, Wang X, Diao T, et al
    Young age increases the risk of lymph-node metastasis in patients with muscle-invasive bladder urothelial carcinoma.
    BMC Cancer. 2020;20:851.
    >> Share

    August 2020
  23. PORSERUD A, Karlsson P, Rydwik E, Aly M, et al
    The CanMoRe trial - evaluating the effects of an exercise intervention after robotic-assisted radical cystectomy for urinary bladder cancer: the study protocol of a randomised controlled trial.
    BMC Cancer. 2020;20:805.
    >> Share

  24. JAMIESON L, Forster MD, Zaki K, Mithra S, et al
    Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study.
    BMC Cancer. 2020;20:743.
    >> Share

    June 2020
  25. MAKELA R, Arjonen A, Harma V, Rintanen N, et al
    Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.
    BMC Cancer. 2020;20:590.
    >> Share

    May 2020
  26. RIPPING TM, Kiemeney LA, van Hoogstraten LMC, Witjes JA, et al
    Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlaZIB).
    BMC Cancer. 2020;20:455.
    >> Share

    March 2020
  27. ZHANG Y, Ou DH, Zhuang DW, Zheng ZF, et al
    In silico analysis of the immune microenvironment in bladder cancer.
    BMC Cancer. 2020;20:265.
    >> Share

  28. PARKER HG, Dhawan D, Harris AC, Ramos-Vara JA, et al
    RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors.
    BMC Cancer. 2020;20:251.
    >> Share

  29. MORSCH R, Rose M, Maurer A, Cassataro MA, et al
    Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
    BMC Cancer. 2020;20:230.
    >> Share

  30. LATIFOVIC L, Villeneuve PJ, Parent ME, Kachuri L, et al
    Silica and asbestos exposure at work and the risk of bladder cancer in Canadian men: a population-based case-control study.
    BMC Cancer. 2020;20:171.
    >> Share

    February 2020
  31. HUPE MC, Dormayer L, Ozimek T, Struck JP, et al
    Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer.
    BMC Cancer. 2020;20:140.
    >> Share

    January 2020
  32. SCHMID SC, Koll FJ, Rodel C, Maisch P, et al
    Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT).
    BMC Cancer. 2020;20:8.
    >> Share

    December 2019
  33. WANG Z, Liu X, Liu X, Sun H, et al
    UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
    BMC Cancer. 2019;19:1195.
    >> Share

    November 2019
  34. BOURN J, Rathore K, Donnell R, White W, et al
    Detection of carcinogen-induced bladder cancer by fluorocoxib A.
    BMC Cancer. 2019;19:1152.
    >> Share

  35. MOLENAAR RJ, van Hattum JW, Brummelhuis IS, Oddens JR, et al
    Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer.
    BMC Cancer. 2019;19:1133.
    >> Share

  36. ZHANG J, Wang Y, Weng H, Wang D, et al
    Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations.
    BMC Cancer. 2019;19:1054.
    >> Share

    October 2019
  37. ALBARAKATI N, Khayyat D, Dallol A, Al-Maghrabi J, et al
    The prognostic impact of GSTM1/GSTP1 genetic variants in bladder Cancer.
    BMC Cancer. 2019;19:991.
    >> Share

    September 2019
  38. YUK HD, Jeong CW, Kwak C, Kim HH, et al
    Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification.
    BMC Cancer. 2019;19:897.
    >> Share

    August 2019
  39. SASSENBERG M, Droop J, Schulz WA, Dietrich D, et al
    Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma.
    BMC Cancer. 2019;19:806.
    >> Share

  40. FIORENTINO V, Pierconti F, Lenci N, Calicchia M, et al
    Urinary bladder leiomyosarcoma with osteoclast-like multinucleated giant cells: a case report.
    BMC Cancer. 2019;19:763.
    >> Share

    July 2019
  41. ZHANG L, Wu B, Zha Z, Qu W, et al
    Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:716.
    >> Share

    June 2019
  42. TRILLA-FUERTES L, Gamez-Pozo A, Prado-Vazquez G, Zapater-Moros A, et al
    Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities.
    BMC Cancer. 2019;19:636.
    >> Share

  43. ZENG S, Liu A, Dai L, Yu X, et al
    Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms.
    BMC Cancer. 2019;19:604.
    >> Share

    April 2019
  44. YASUI M, Kawahara T, Izumi K, Yao M, et al
    Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer.
    BMC Cancer. 2019;19:331.
    >> Share

    March 2019
  45. PANG K, Zhang Z, Hao L, Shi Z, et al
    The ERH gene regulates migration and invasion in 5637 and T24 bladder cancer cells.
    BMC Cancer. 2019;19:225.
    >> Share

  46. LV S, Wang W, Wang H, Zhu Y, et al
    PPARgamma activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway.
    BMC Cancer. 2019;19:204.
    >> Share

    February 2019
  47. GOULET CR, Champagne A, Bernard G, Vandal D, et al
    Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling.
    BMC Cancer. 2019;19:137.
    >> Share

    January 2019
  48. AL-HUSSEINI MJ, Kunbaz A, Saad AM, Santos JV, et al
    Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis.
    BMC Cancer. 2019;19:46.
    >> Share

    December 2018
  49. MATHIS C, Lascombe I, Monnien F, Bittard H, et al
    Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up.
    BMC Cancer. 2018;18:1239.
    >> Share

  50. RACIOPPI M, Di Gianfrancesco L, Ragonese M, Palermo G, et al
    ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
    BMC Cancer. 2018;18:1224.
    >> Share

    November 2018
  51. WANG L, Chen S, Zhang Z, Zhang J, et al
    Suppressed OGT expression inhibits cell proliferation while inducing cell apoptosis in bladder cancer.
    BMC Cancer. 2018;18:1141.
    >> Share

  52. ZHOU T, Li HY, Xie WJ, Zhong Z, et al
    Association of Glutathione S-transferase gene polymorphism with bladder Cancer susceptibility.
    BMC Cancer. 2018;18:1088.
    >> Share

  53. WANG Z, Xiao H, Wei G, Zhang N, et al
    Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model.
    BMC Cancer. 2018;18:1108.
    >> Share

    October 2018
  54. STEFFENSEN EH, Cary C, Jensen JB, Larsson H, et al
    Preadmission antidepressant use and bladder cancer: a population-based cohort study of stage at diagnosis, time to surgery, and surgical outcomes.
    BMC Cancer. 2018;18:1035.
    >> Share

    September 2018
  55. WIJBURG CJ, Michels CTJ, Oddens JR, Grutters JPC, et al
    Robot assisted radical cystectomy versus open radical cystectomy in bladder cancer (RACE): study protocol of a non-randomized comparative effectiveness study.
    BMC Cancer. 2018;18:861.
    >> Share

    June 2018
  56. LIU H, He W, Wang B, Xu K, et al
    MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
    BMC Cancer. 2018;18:659.
    >> Share

  57. LIU Y, Wang H, Zhong J, Wu C, et al
    Decreased expression of SRY-box containing gene 30 is related to malignant phenotypes of human bladder cancer and correlates with poor prognosis.
    BMC Cancer. 2018;18:642.
    >> Share

    May 2018
  58. KWON WA, Joung JY, Lim J, Oh CM, et al
    Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea.
    BMC Cancer. 2018;18:617.
    >> Share

  59. XIE H, Zhu Y, Zhang J, Liu Z, et al
    B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients.
    BMC Cancer. 2018;18:590.
    >> Share

    April 2018
  60. MAEDA S, Tomiyasu H, Tsuboi M, Inoue A, et al
    Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq.
    BMC Cancer. 2018;18:472.
    >> Share

    February 2018
  61. PULIDO M, Roubaud G, Cazeau AL, Mahammedi H, et al
    Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.
    BMC Cancer. 2018;18:194.
    >> Share

  62. SEVERINO PF, Silva M, Carrascal M, Malagolini N, et al
    Oxidative damage and response to Bacillus Calmette-Guerin in bladder cancer cells expressing sialyltransferase ST3GAL1.
    BMC Cancer. 2018;18:198.
    >> Share

    December 2017
  63. ZHANG Z, Zhang G, Gao Z, Li S, et al
    Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer.
    BMC Cancer. 2017;17:861.
    >> Share

    November 2017
  64. HUEBNER D, Rieger C, Bergmann R, Ullrich M, et al
    An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment.
    BMC Cancer. 2017;17:790.
    >> Share

  65. TAN WS, Feber A, Dong L, Sarpong R, et al
    DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.
    BMC Cancer. 2017;17:767.
    >> Share

  66. TOLKACH Y, Stahl AF, Niehoff EM, Zhao C, et al
    YRNA expression predicts survival in bladder cancer patients.
    BMC Cancer. 2017;17:749.
    >> Share

    September 2017
  67. NEUZILLET Y, Chapeaublanc E, Krucker C, De Koning L, et al
    IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer.
    BMC Cancer. 2017;17:636.
    >> Share

    June 2017
  68. PENG D, Gong YQ, Hao H, He ZS, et al
    Preoperative Prognostic Nutritional Index is a Significant Predictor of Survival with Bladder Cancer after Radical Cystectomy: a retrospective study.
    BMC Cancer. 2017;17:391.
    >> Share

    May 2017
  69. TEYSSONNEAU D, Daste A, Dousset V, Hoepffner JL, et al
    Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.
    BMC Cancer. 2017;17:323.
    >> Share

  70. FONTEYNE V, Dirix P, Junius S, Rammant E, et al
    Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial.
    BMC Cancer. 2017;17:308.
    >> Share

    April 2017
  71. KAO YT, Wu CH, Wu SY, Lan SH, et al
    Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells.
    BMC Cancer. 2017;17:277.
    >> Share

  72. LAVERY HJ, Zaharieva B, McFaddin A, Heerema N, et al
    A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection.
    BMC Cancer. 2017;17:247.
    >> Share

    March 2017
  73. MIYAKE M, Morizawa Y, Hori S, Marugami N, et al
    Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder.
    BMC Cancer. 2017;17:237.
    >> Share

    February 2017
  74. DYSHLOVOY SA, Madanchi R, Hauschild J, Otte K, et al
    The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.
    BMC Cancer. 2017;17:93.
    >> Share

    January 2017
  75. BAI Y, Wang X, Yang Y, Tang Y, et al
    Parity and bladder cancer risk: a dose-response meta-analysis.
    BMC Cancer. 2017;17:31.
    >> Share

    November 2016
  76. KONG C, Zhan B, Piao C, Zhang Z, et al
    Overexpression of UNC5B in bladder cancer cells inhibits proliferation and reduces the volume of transplantation tumors in nude mice.
    BMC Cancer. 2016;16:892.
    >> Share

  77. BENHAMOU S, Bonastre J, Groussard K, Radvanyi F, et al
    A prospective multicenter study on bladder cancer: the COBLAnCE cohort.
    BMC Cancer. 2016;16:837.
    >> Share

    January 2016
  78. ANANTHARAMAN A, Friedlander T, Lu D, Krupa R, et al
    Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
    BMC Cancer. 2016;16:744.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016